Literature DB >> 19078948

A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.

E Hénin1, B You, E VanCutsem, P M Hoff, J Cassidy, C Twelves, K P Zuideveld, F Sirzen, C Dartois, G Freyer, M Tod, P Girard.   

Abstract

For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used. Of 595 patients in the capecitabine arms, 400 patients were randomly selected to build the model, and the other 195 were assigned for model validation. A score for risk of developing HFS was modeled using the proportional odds model, a sigmoidal maximum effect model driven by capecitabine accumulation as estimated through a kinetic-pharmacodynamic model and a Markov process. The lower the calculated creatinine clearance value at inclusion, the higher was the risk of HFS. Model validation was performed by visual and statistical predictive checks. The predictive dynamic model of HFS in patients receiving capecitabine allows the prediction of toxicity risk based on cumulative capecitabine dose and previous HFS grade. This dose-toxicity model will be useful in developing Bayesian individual treatment adaptations and may be of use in the clinic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19078948     DOI: 10.1038/clpt.2008.220

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

Review 1.  Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.

Authors:  Núria Buil-Bruna; José-María López-Picazo; Salvador Martín-Algarra; Iñaki F Trocóniz
Journal:  Oncologist       Date:  2015-12-14

2.  A Minimal Continuous-Time Markov Pharmacometric Model.

Authors:  Emilie Schindler; Mats O Karlsson
Journal:  AAPS J       Date:  2017-06-20       Impact factor: 4.009

3.  A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins.

Authors:  Qing Xi Ooi; Daniel F B Wright; R Campbell Tait; Geoffrey K Isbister; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

Review 4.  Pharmacodynamic models for discrete data.

Authors:  Ines Paule; Pascal Girard; Gilles Freyer; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

5.  Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder.

Authors:  Bill Frame; Raymond Miller; Matthew M Hutmacher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-08       Impact factor: 2.745

6.  SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.

Authors:  Xin Liao; Liu Huang; Qianqian Yu; Siyuan He; Qianxia Li; Chao Huang; Xianglin Yuan
Journal:  Cancer Chemother Pharmacol       Date:  2020-03-19       Impact factor: 3.333

7.  Risk prediction models based on hematological/body parameters for chemotherapy-induced adverse effects in Chinese colorectal cancer patients.

Authors:  Mingming Li; Jiani Chen; Yi Deng; Tao Yan; Haixia Gu; Yanjun Zhou; Houshan Yao; Hua Wei; Wansheng Chen
Journal:  Support Care Cancer       Date:  2021-07-02       Impact factor: 3.603

8.  Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer.

Authors:  R Bruno; L Lindbom; F Schaedeli Stark; P Chanu; F Gilberg; N Frey; L Claret
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-12-26

9.  PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST.

Authors:  E K Hansson; G Ma; M A Amantea; J French; P A Milligan; L E Friberg; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-12-04

Review 10.  Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.

Authors:  Brendan C Bender; Emilie Schindler; Lena E Friberg
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.